LWCFA
ABUS icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Arbutus Biopharma ABUS Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$648 – 519
2025
Q1 		$648 Buy
+200
New +$667 ﹤0.01% 539

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's ABUS Position: Q2 2025 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Arbutus Biopharma (ABUS) in Q2 2025, closing a stake of 200 shares — an estimated $648 sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in ABUS in Q1 2025 and held it in 1 quarter. The position peaked at $648 in Q1 2025. 162 funds tracked by Wall St. Rank hold ABUS as of Q2 2025.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Arbutus Biopharma position as of Q2 2025 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 200 Arbutus Biopharma shares in Q2 2025, an estimated $648.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Arbutus Biopharma in Q1 2025 and held it in 1 quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Arbutus Biopharma position peaked at $648 in Q1 2025.
  • 162 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2025.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.